FDA AdComm Prep For Gilead’s Sofosbuvir Shows Agency Thinking On HCV Dosing
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA staff cites a favorable benefit-risk assessment for sofosbuvir, though evidence is insufficient to support dosing recommendation in patients with HCV genotypes 5 and 6. Dosing duration and use in prior nonresponders and pre-transplant patients will be discussed by Antiviral Drugs Advisory Committee Oct. 25.